Effect tDCS of Motor Cortex on Chemotherapy Induced Peripheral Neuropathy

Assiut University

Status: Unknown

Conditions: Chemotherapy-induced Peripheral Neuropathy

Treatments: Device: transcranial dirrect current brain stimuation

Study type: Interventional

Funder types: Other

Identifiers

NCT04833920

539

Details and patient eligibility

About

Chemotherapy induced peripheral neuropathy (CIPN) occurs in conjunction with the use of anticancer medication such as vinca alkaloids (including vincristine), taxanes (including paclitaxel), and platinum preparations (including cisplatin and oxaliplatin)

Full description

Chemotherapy induced peripheral neuropathy (CIPN) occurs in conjunction with the use of anticancer medication such as vinca alkaloids (including vincristine), taxanes (including paclitaxel), and platinum preparations (including cisplatin and oxaliplatin) . CIPN is one of several long term side effects of anticancer medications that can appear during and after treatment. CIPN symptoms include pain, dysesthesia, motor and sensory disorders. CIPN can also be insufficiently responsive to pharmaceutical therapy similar to other types of refractory neuropathic pain This study is designed to evaluate the effect of two concentric electrode transcranial direct current stimulation (CE-tDCS) over the primary motor cortex (M) in management of chemotherapy induced peripheral neuropathy.

Enrollment: 26 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• any stage of cancer, with a confirmed treatment plan consisting of taxane-based or oxaliplatin-based chemotherapy, neuropathic pain and/or peripheral sensory neuropathy with VAS score ≥ 3 that are resistant to medical treatment

Exclusion criteria

• patients with intracranial metallic devices or with pacemakers or any other device. - -W those with extensive myocardial ischemia,
• higher brain dysfunction,
• migraine headache,
• brain cancer or metastasis and
• those known to have epilepsy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

26 participants in 2 patient groups

active tDCS

Active Comparator group

Description:

tDCS targeting the primary motor cortex of the contralateral side of the painful side for 20 minute duration for five sessions in five consecutive days

Treatment:

Device: transcranial dirrect current brain stimuation

sham tDCS

Sham Comparator group

Description:

tDCS over the primary motor cortex in the same stimulation parameters will be used but the device will be turned off without patient knowledge after 30 seconds

Treatment:

Device: transcranial dirrect current brain stimuation